RB1 and large cell neuroendocrine carcinoma: Recently, several retrospective clinical studies have found differences in prognosis and treatment outcomes of LCNEC patients based on molecular subtype, as determined primarily by the status of Rb (by molecular testing and/or IHC)101,102.